Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

5.59USD
24 Mar 2017
Change (% chg)

$-0.05 (-0.89%)
Prev Close
$5.64
Open
$5.69
Day's High
$5.69
Day's Low
$5.40
Volume
35,787
Avg. Vol
34,410
52-wk High
$8.04
52-wk Low
$3.29

Latest Key Developments (Source: Significant Developments)

Genocea reports Q4 loss per share $0.56
Thursday, 16 Feb 2017 07:30am EST 

Genocea Biosciences Inc : Genocea reports fourth quarter and year-end 2016 financial results . Positive phase 2B clinical data confirm attractive profile for GEN-003; expected to start phase 3 program in 4Q 2017 . Neoantigen cancer vaccine program on track to file first IND by end of 2017 .Qtrly loss per share $0.56.  Full Article

Genocea qtrly loss per share $0.39
Thursday, 4 Aug 2016 07:30am EDT 

Genocea Biosciences Inc : Genocea reports second quarter 2016 financial results . Qtrly loss per share $0.39 .Expects that cash, cash equivalents to be sufficient to fund operating expenses, capex requirements into second half of 2017.  Full Article

Genocea Biosciences Inc announces top-line results from Phase 2a Trial for universal pneumococcal vaccine candidate GEN-004
Monday, 19 Oct 2015 07:00am EDT 

Genocea Biosciences Inc:Announces top-line results from Phase 2a Trial for universal pneumococcal vaccine candidate GEN-004.Says development suspended pending further review of data and potential paths forward.Says consistent reductions versus placebo in rate and density of colonization; not statistically significant.Says gen-004 was safe and well tolerated by subjects.Gen-004 reduced colonization rate, measured by microbiological culture, by between 22 and 25 percent versus placebo.Says there was no difference in the duration of colonization between gen-004 and placebo.Says none of the differences in study were statistically significant.For the time being, removing the development of gen-004 from our near-term plans.  Full Article

Genocea Biosciences, Inc announces closing of public offering of common stock
Tuesday, 4 Aug 2015 09:07am EDT 

Genocea Biosciences, Inc:Closes its public offering of 3,850,000 shares of its common stock, at the public offering price of $13.00 per share.Net proceeds to Genocea from this offering are expected to be about $47 mln.Cowen and Company, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering.  Full Article

Genocea Biosciences, Inc announces pricing of public offering
Thursday, 30 Jul 2015 08:05am EDT 

Genocea Biosciences, Inc:Announces pricing of $50 million public offering.Says public offering of 3.9 million common shares priced at $13.00 per share.  Full Article

Genocea Biosciences commences public offering of common stock
Wednesday, 29 Jul 2015 04:01pm EDT 

Genocea Biosciences Inc:Intends to offer and sell shares of its common stock in an underwritten public offering.Grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public.Cowen and Company, Piper Jaffray & Co. and Stifel are acting as joint book-running managers for the offering and Needham & Company is acting as co-manager.  Full Article

Genocea Biosciences announces positive top-line phase 2 data for Genital Herpes Immunotherapy GEN-003
Wednesday, 20 May 2015 07:00am EDT 

Genocea Biosciences Inc:Positive top-line data from Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.During 28-day observation period immediately after completion of dosing, dose of 60 µg per protein / 75 µg of Matrix-M2 adjuvant demonstrated statistically 55 pct reduction from baseline in viral shedding rate, primary endpoint of trial and measure of anti-viral activity.All dose combinations tested, including 30 µg per protein / 50 µg of adjuvant dose from prior Phase 1/2a trial, demonstrated statistically viral shedding rate reduction versus baseline and only lowest dose combination did not demonstrate statistically reduction versus placebo.  Full Article

More From Around the Web

BRIEF-Genocea reports Q4 loss per share $0.56

* Genocea reports fourth quarter and year-end 2016 financial results